Symposium - New York City, United States
Graft-versus-host disease (GvHD) is the major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplant (HSCT). Allogeneic HCST is most commonly performed as a treatment for hematological malignancies, thus a crucial consideration when treating GvHD is to inhibit the pathological mechanisms that cause GvHD while at the same time ensuring the graft-versus-tumor (GvT) response is preserved. It is therefore critical for transplant physicians and drug discovery scientists alike to understand the immunologic pathways that underlie both the beneficial GvT and the harmful GvH responses.
This symposium will bring together clinical, basic, and industry scientists to discuss the current and emerging treatment options for GvHD, highlight recent advances in our understanding of disease and anti-tumor immune pathways, and will suggest new approaches to develop immunomodulatory therapies to separate GvHD from GvT effects.
Organization: New York Academy of Sciences
(Courtesy of Graft-versus host disease (GVHD), via medindia.net)
Tuesday, February 18, 2014 | 8:30 AM - 4:30 PM
New York Academy of Sciences
250 Greenwich Street, 40th Floor, New York City, United States
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.